Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti Viral Treatment in Mild Cognitive Impairment
NCT04710030Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Feb 2021
- Primary completion
- Oct 2024
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Mild Cognitive Impairment (MCI) comparing Valacyclovir with Placebo (2 arms). Primary endpoint: Standardized Uptake Value Ratio at 52 weeks. Started Feb 2021; status: completed.
02
Drugs
valaciclovir
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT04710030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04710030.